miR‐138‐5p inhibits the progression of colorectal cancer via regulating SP1/LGR5 axis.

Colorectal cancer (CRC) is one of the main malignancies that seriously threaten human health. Considering the high mortality and morbidity associated with this disease, even surgical resection and chemotherapy may not be sufficient in certain cases. This study aimed to explore the molecular mechanisms of miR‐138‐5p in regulating CRC progression. Quantitative reverse transcriptase polymerase chain reaction and western blot were performed to assess the levels of mRNA and proteins, including miR‐138‐5p, leucine‐rich repeat‐containing G protein‐coupled receptor 5 (LGR5), SP1, β‐catenin, cyclin D1, and c‐myc. The bioactivities of LoVo and HCT116 cells were assessed via MTT assay, flow cytometry, and transwell assay. StarBase was used to identify the downstream targets of genes. Double luciferase reporter and RIP assays revealed the direct binding of miR‐138‐5p to SP1 and of SP1 to LGR5. Our results illustrated that miR‐138‐5p was downregulated in CRC and its knockdown accelerated CRC progression. Conversely, SP1 was upregulated in CRC and its knockdown inhibited CRC progression. SP1 is also targeted by miR‐138‐5p and binds to LGR5. This study showed that miR‐138‐5p inhibits LoVo and HCT116 cell proliferation, migration, and invasion. Overall, miR‐138‐5p regulates CRC progression and promotes apoptosis via the SP1/LGR5 axis. This study indicates that miR‐138‐5p is involved in regulating CRC progression. [ABSTRACT FROM AUTHOR]